Learning and research

25 March 2021

SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell
Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai

PVRI Digital Webinar Series

25 February 2021

Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan
Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington

PVRI Digital Webinar Series

11 February 2021

The view of the World Heart Federation (WHF), Fausto Pinto
Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME), Sophia Emmons-Bell
PVRI GoDeep: Perspectives of a global meta-registry, Werner Seeger
Mortality of idiopathic/hereditary and connective tissue disease-associated pulmonary arterial hypertension: the data from first single center prospective registry in Indonesia, Anggoro Budi Hartopo
Triple therapy in pulmonary arterial hypertension in an expert centre in Mexico City. Real-life results, Humberto Garcia-Aguilar

PVRI Digital Webinar Series

Related content